Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S2468-1253(24)00124-9 | DOI Listing |
Publication Analysis
Top Keywords
resmetirom mash-related
4
mash-related cirrhosis
4
resmetirom
1
cirrhosis
1
Similar Publications
Resmetirom for MASH-related cirrhosis.
Lancet Gastroenterol Hepatol
July 2024
Metabolic Dysfunction-Associated Fatty Liver Disease Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China; Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, Zhejiang, China. Electronic address:
Article Synopsis
- Metabolic dysfunction-associated steatotic liver disease (MASLD) refers to liver disease characterized by fat accumulation in the liver, often linked to metabolic risk factors, and includes various stages from simple fat accumulation (steatosis) to more severe conditions like cirrhosis and liver cancer.* -
- Updated guidelines emphasize the importance of screening for MASLD in individuals with cardiovascular risk factors and propose using non-invasive tests and blood-based scores to identify liver fibrosis.* -
- Treatment strategies focus on lifestyle changes, managing related health conditions, and possible medical interventions, such as drugs for diabetes and obesity, with bariatric surgery as an option for those with obesity; specific treatments exist for non-cirrhotic stages but not for
Article Synopsis
- Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is characterized by fat accumulation in the liver related to metabolic risk factors, excluding alcohol consumption.
- The condition spans a range from simple fat accumulation to more severe stages like metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and even liver cancer.
- Recommended management includes lifestyle changes, such as weight loss and diet modifications, non-invasive screening for liver fibrosis in at-risk populations, and potential pharmacotherapy options like resmetirom for significant liver fibrosis.
Article Synopsis
- Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by fat accumulation in the liver alongside cardiometabolic risk factors and occurs without excessive alcohol consumption; it ranges from mild steatosis to severe liver conditions like cirrhosis and potentially cancer.
- The EASL-EASD-EASO guideline emphasizes the importance of identifying MASLD, especially in patients with type 2 diabetes or obesity, through non-invasive tests, and provides a structured approach for evaluating and diagnosing liver fibrosis.
- Recommended management strategies for MASLD include lifestyle changes (like diet and exercise), treatment of related health issues (such as using medications for diabetes), and consideration of options like bariatric surgery or specific treatments for significant liver fibrosis
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!